clinical trial · NCT05776134
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel
Kite, A Gilead Company·—·available
Mantle Cell LymphomaAcute Lymphoblastic LeukemiaBrexucabtagene Autoleucel
brief summary
The goal of this study is to provide access to brexucabtagene autoleucel for patients diagnosed with a disease approved for treatment with brexucabtagene autoleucel, that is otherwise out of specification for commercial release.
started
—
primary completion
—
completion
—
last updated
Apr 8, 2026
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol